Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03286114 · ClinicalTrials.gov registry record · Phase 1
Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab
A Phase 1 study, sponsored by University of Michigan Rogel Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT03286114 is a Phase 1 study that was terminated before completion, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 16 participants.
The verdict
NCT03286114, a Phase 1 study, was terminated before completion, sponsored by University of Michigan Rogel Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is a single arm, open-label, Phase 1b study of pembrolizumab for patients with myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL) whose disease has relapsed after receiving allogeneic hematopoetic stem cell transplant.
Interventions
- DRUG Pembrolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2017-12-21 |
| Est. Completion | 2021-04-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03286114
The ClinicalTrials.gov registry entry for NCT03286114 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT03286114 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03286114 about?
NCT03286114 is a clinical study titled "Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab". This is a single arm, open-label, Phase 1b study of pembrolizumab for patients with myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL) whose disease has relapsed after receiving allogeneic hematopoetic stem cell transplant.
What is the current status of trial NCT03286114?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2017-12-21. Estimated completion is 2021-04-28.
What interventions are being tested in trial NCT03286114?
The interventions under investigation include: Pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT03286114?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.